Osteoporosis and inflammatory bowel disease;Osteoporosis y enfermedad inflamatoria intestinal

Nutricion Hospitalaria

Volumn 20, Issue 1, 2005, Pages 26-37

  Menchen L ^a   Ripoll, C ^a   Bretón, Irene ^a   Moreno, C ^a   De La Cuerda, C ^a   Camblor, M ^a   Garcia Peris P ^a   Gonzalez Lara V ^a   Cos, E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Crohn's disease; Inflammatory bowel disease; Osteoporosis; Ulcerative colitis

Indexed keywords

CORTICOSTEROID;

CLINICAL FEATURE; CONFERENCE PAPER; ENTERITIS; GASTROINTESTINAL TRACT; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOLOGY; NUTRITIONAL DEFICIENCY; OSTEOPENIA; OSTEOPOROSIS; ARTICLE; BONE DENSITY; CLINICAL TRIAL; RADIODENSITOMETRY;

BONE DENSITY; CLINICAL TRIALS; DENSITOMETRY, X-RAY; HUMANS; INFLAMMATORY BOWEL DISEASES; OSTEOPOROSIS;

EID: 17244382378     PISSN: 02121611     EISSN: 02121611     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (116)

1. Heaney RP: Bone biology in health and disease: a tutorial. En: Shills ME, Olson JA, Shine M, Ross AC. Modern Nutrition in Health and Disease. 9th ed. Baltimore: Williams & Wilkins. 1999, 1327-1338.
2. Heaney RP: Pathophysiology of osteoporosis. Endocrinol Metab Clin North Am 1998, 27(2):255-265.
3. Krall EA, Dawson-Hughes B: Osteoporosis. En: Shills ME, Olson JA, Shine M, Ross AC. Modern Nutrition in Health and Disease. 9th ed. Baltimore: Williams & Wilkins. 1999, 1353-1364.
4. Harper KD, Weber TJ: Secondary osteoporosis. Endocrinol Metab Clin North Am 1998, 27(2):325-348.
5. Ross PD: Risk factors for osteoporotic fractures. Endocrinol Metab Clin North Am 1998, 27(2):289-301.
6. Sinaki M: Exercise and osteoporosis. Arch Phys Med Rehabil 1989, 70:220-9.
7. Henderson NK, White CP, Eisman JA: The roles of exercise and fall risk reduction in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998, 27(2):369-387.
8. Felson DT, Kiel DP, Anderson JJ, Kannel WB: Alcohol consumption and hip fracture: the Framingham study. Am J Epidemiol 1998, 128:1102-1110.
9. Krall EA, Dawson-Hughes B: Smoking and bone loss among postmenopausal women. J Bone Miner Res 1991, 6:331-8.
10. Slemenda CW, Christian J, Reed T, Reister TK, Williams CJ, Johnston CC Jr: Long-term bone loss in men: effects of genetic and environmental factors. Ann Intern Med 1992, 117:286-291.
11. Blake GM, Fogelman I: Applications of bone densitometry for osteoporosis. Endocrinol Metab Clin North Am 1998, 27(2):267-288.
12. Fries W, Dinca M, Luisetto G, Peccolo F, Bottega F, Martin A: Calcaneal ultrasound bone densitometry in inflammatory bowel disease - a comparision with double x-ray densitometry of the lumbar spine. Am J Gastroenterol 1998, 93:2339-44.
13. Jahnsen J, Falch JA, Mowinckel P, Aadland E: Ultrasound measurements of calcaneus for estimation of skeletal status in patients with inflammatory bowel disease. Scand J Gastroenterol 1999, 34:790-7.
14. Levine A, Mishna L, Ballin A, Givoni S, Dinari G, Hartman C, Shamir R: Use of quantitative ultrasound to assess osteopenia in children with Crohn disease. J Pediatr Gastroenterol Nutr 2002, 35:169-172.
15. Von Tirpitz C, Klaus J, Steinkamp M, Mason R, Kratzer W, Adler G, Rieber A, Reinshagen M: Quantitative ultrasound of the proximal phalanges and dual-energy X-ray absorptiometry in Crohn's disease patients with osteopenia. J Gastroenterol 2003, 38:238-243.
16. World Health Organization: Assesment of fractures risk and its application to screening for menopausal osteoporosis. Technical Reports Series Number 843. Geneva: World Health Organization, 1994.
17. Garnero P, Delmas PD: Biochemical markers of bone turnover. Applications for osteoporosis. Endocrinol Metab Clin North Am 1998, 27(2):303-323.
18. Ledro Cano D, Torres Dominguez Y, Castro Laria L, Sáenz Dana M, Herrerías Esteban JM, Herrerías Gutierrez JM: Los marcadores bioquímicos y la densitometría ósea en la enfermedad inflamatoria intestinal. Rev Esp Enferm Dig 2000, 92:595-600.
19. Riss BJ, Overgaard K, Christiansen C: Biochemical markers of bone turnover to monitor the bone mass response to post-menopausal hormone replacement therapy. Osteoporos Int 1995, 5:276-280.
20. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD: Comparision of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994, 79:1693-1700.
21. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D: Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol 2000, 95:699-704.
22. Faust D, Menge F, Armbruster FP, Lembcke B, Stein J: Increased serum bone sialoprotein concentrations in patients with Crohn's disease. Z Gastroenterol 2003, 41:243-247.
23. Valentine JF, Sninsky CA: Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999, 94:878-83.
24. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L: Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997, 32:1247-55.
25. Ghosh S, Meister D: Osteopenia in inflammatory bowel disease. Research and Clinical Forums 2000, 22:159-170.
26. Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE: Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporos Int 1993, 3:236-41.
27. Lin CL, Moniz C, Chambers TJ, Chow JW: Colitis causes bone loss in rats through supression of bone formation. Gastroenterology 1996, 111:1263-71.
28. Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE: Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988, 29:1332-1336.
29. Robinson RJ, Iqbal SJ, Abrams K, Al Azzawi F, Mayberry JF: Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998, 12:699-705.
30. Clements D, Motley RJ, Evans WD, Harries AD, Rhodes J, Coles RJ, Compston JE: Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992, 27:1055-60.
31. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J: Osteoporosis in patients with inflammatory bowel disease. Gut 1987, 28:410-415.
32. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B: Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995, 108:417-422.
33. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy Montbrun T, Listrat V, Dougados M, Couturier D, Amor B: Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992, 37:1396-1403.
34. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK: A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995, 37:71-76.
35. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C: Reduced bone density in patients with inflammatory bowel disease. Gut 1997, 40:228-233.
36. Staun M, Tjellesen L, Thaïe M, Schaadt O, Jarnum S: Bone mineral content in patients with Crohn's disease. A longitudinal study in patients with bowel resections. Scand J Gastroenterol 1997, 32:226-232.
37. Pollak RD, Karmell F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D: Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998, 93:1483-1490.
38. Schulte C, Dignass AU, Mann K, Goebell H: Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 1999, 34:696-702.
39. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS: Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998, 114:902-911.
40. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrügger RW Brummer RJ: Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000, 119:1203-1208.
41. Martínez N, López-Rodríguez F, Mezquita-Raya P, Muñoz-Torres M, González J: Factores relacionados con la pérdida de masa ósea en pacientes diagnosticados de enfermedad inflamatoria intestinal. Endocrinologia 2001, 48 (Supl. 2):45-46.
42. Dear KL, Compston JE, Hunter JO: Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clin Nutr 2001, 20:541-546.
43. Klaus J, Armbrecht G, Steinkamp M, Bruckel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C: High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002, 51:654-658.
44. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN: The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 2000, 133:795-799.
45. Van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK: Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003, 125:1591-1597.
46. Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ: 3rd. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002, 123:468-475.
47. Robinson RJ, Al-Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF: Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998, 43:2500-2506.
48. Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF: Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998, 12:21-25.
49. Jahnsen J, Falch JA, Mowinckel P, Aadland E: Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol 2003, 98:1556-62.
50. Nemetz A, Toth M, García-González MA, Zagoni T, Feher J, Peña AS, Tulassay Z: Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel disease. Gut 2001, 49:644-9.
51. Schulte CMS, Dignass AU, Goebell H, Röher HD, Schulte KM: Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000, 119:909-920.
52. Niessner M, Volk BA: Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995, 101:428-435.
53. Podolsky DK, Fiocchi C: En: Kirsner JB, eds.: Inflammatory Bowel Disease. Philadelphia, USA. Saunders Company, 2000, p. 191-207.
54. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J: Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001, 86(5):2032-42.
55. Manolagas SC: The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci 1998, 840:194-204.
56. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA: Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002, 17:695-702.
57. Holub MC, Mako E, Devay T, Dank M, Szalai C, Fenyvesi A, Falus A: Increased interleukin-6 levels, and gp 130 expression in peripheral lympocytes of patients with inflammatory bowel disease. Scand J Gastroenterol Suppl 1998, 228:47-50.
58. Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, Mary JY: A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 1997, 9:939-944.
59. Van Kemseke, Belaiche J, Louis E: Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis 2000, 15:206-210.
60. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, Compston JE: A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993, 23:95-104.
61. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM: Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998, 42:188-94.
62. Robinson RJ, Iqbal SJ, Wolfe R, Patel K, Abrams K, Mayberry JF: The effect of rectally administered steroids on bone turnover: a comparative study. Aliment Pharmacol Ther 1998, 12:213-7.
63. De Jong DJ, Corstens FH, Mannaerts L, van Rossum LG, Naber AH: Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol 2002, 97 (8):2011-5.
64. Gassull MA: New insights in nutritional therapy in inflammatory bowel disease. Clin Nutr 2001, 20(suppl 1):113-121.
65. Issenman RM, Atkinson SA, Radoja C, Fraher L: Longitudinal assesment of growth, mineral metabolism, and bone mass in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1993, 17:401-6.
66. Griffiths AM: Enfermedad de Crohn en los niños y adolescentes: ¿cuáles son las opciones de tratamiento? Drugs Today (Barc) 1999, 35(Suppl 7):5-17.
67. Kanof ME, Lake AM, Bayless TM: Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988, 95:1523-7.
68. Thearle M, Horlick M, Bilezikian JP, Levy J, Gertner JM, Levine LS, Harbison M, Berdon W, Oberfield SE: Osteoporosis: an unusual presentation of childhood Crohn's disease. J Clin Endocrinol Metab 2000, 85:2122-26.
69. Alpers DH: The role of nutritional deficiency in the osteopenia and osteoporosis of gastrointestinal diseases. Curr Opin Gastroenterol 2002; 18:203-208.
70. Krok KL, Lichtenstein GR: Nutrition in Crohn disease. Curr Opin Gastroenterol 2003, 19:148-153.
71. Driscoll RH, Meredith SC, Sitrin M, Rosenberg IH: Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982, 83:1252-8.
72. Siffledeen JS, Siminiski K, Steinhart H, Greenberg G, Fedorak RN: The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol 2003, 17(8):437-8.
73. Szulc P, Meunier PJ: Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease? Lancet 2001, 357:1995-6.
74. Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW: Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenic factor of osteoporosis in Crohn's disease? Gut 2001, 48:473-7.
75. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L: Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000, 46:176-181.
76. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi-Porro G: Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000, 247:63-70.
77. Von Tirpitz C, Steder-Neukamm U, Glas K, Sander S, Ring C, Klaus J, Reinshagen M: Osteoporosis in inflammatory bowel disease - results of a survey among members of the German Crohn's and Ulcerative Colitis Association. Z Gastroenterol 2003, 41(12):1145-50.
78. Lane NE, Lukert B: The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998, 27(2):466-483.
79. Compston JE: Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther 1995, 9:237-50.
80. Scott EM, Gaywood I, Scott BB: Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. Gut 2000, 46(suppl 1): 11-18.
81. Papaioannou A, Ferko NK, Adachi JD: All patients with inflammatory bowel disease should have bone density assesment: pro. Inflamm Bowel Dis 2001, 7:158-162.
82. Robinson R, Kryswcki T, Almond L, Al-Azzawi F, Abrams K, Iqbal SJ, Mayberry JF: Effect of low-impact exercise program on bone mineral density in Crohn's disease: a randomised control trial. Gastroenterology 1998, 115:36-41.
83. Silvenoinnen JA, Lehtola JK, Niemela SE: Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996, 31:367-71.
84. American Gastroenterological Association. AGA technical review on osteoporosis in gastroinestinal diseases. Gastroenterology 2003, 124:795-841.
85. Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold C, Frotz S, Gangl A: Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci 1989, 34:1094-9.
86. Vogelsang H, Ferenci P, Resch H y cols.: Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995, 7:609-14.
87. Colvard DS, Eriksen EF, Keeling PE, Wilson DB, French FS: Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 1989, 86:854-7.
88. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA: Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987, 317:169-74.
89. Clements D, Compston JE, Evans WD, Rhodes J: Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993, 34:1543-60.
90. Liberman UA, Weiss SL, Broll J, Minne HW, Quan H, Bell NH, Rodríguez-Portales J, Downs RW Jr, Dequeker J, Favus M: The efffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-43.
91. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604-10.
92. Saag KG, Emkey R, Schintzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifrotis AG: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292-299.
93. Lin CL, Moniz C, Chow JW: Treatment with fluoride or biphosphonates prevents bone loss associated with colitis in the rat. Calcif Tissue Int 2000, 67:373-7.
94. Haderslev KV, Tjellesen H, Sorensen A, Staun M: Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000, 119:639-646.
95. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP: A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003, 18(11-12): 1121-7.
96. Avioli LV: The role of calcitonin in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998, 27(2):411-17.
97. Von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G, Bohm BO, Reinshagen M: Increased of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000, 12:19-24.
98. Von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M: Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003, 17:807-816.
99. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
100. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
101. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
102. American College of Rheumatology. Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996, 39:1791-1801.
103. D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P: Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998, 12:419-24.
104. Spencer CM, McTavish D: Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995, 50:854-72.
105. Cino M, Greenberg GR: Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002, 97:915-921.
106. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a three year follow up. J Rheumatol 1996, 23:995-1000.
107. Bijlsma JWJ, Raymakers JA, Mosch C, Hoekstra A, Derksen RH, Baart de la Faille, Duursma SA: Effects of oral calcium and vitamin D on glucocorticoid osteopenia. Clin Exp Rheumatol 1988, 6:113-19.
108. Brown JJ, Birkenhager-Frenkel DH, Rietveld JR y cols.: Influence of 1-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment: a double blind controlled study. Clin Endocrinol 1983, 19:265-73.
109. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996, 125:961-8.
110. Dykman TR, Haraldson KM, Gluck OS, Murphy WS, Teitelbaum SL, Hahn TJ, Hahn BH: Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984, 27:1336-43.
111. Di Munno O, Beghe F, Favini P, Di Giuseppe P, Pontrandolfo A, Occhipinti G, Pasero G: Prevention of glucocorticoid osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol 1989, 8:202-7.
112. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH: Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest 1979, 64:655-65.
113. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J: Prevention of corticosteroid osteoporosis - a comparision of calcium, calcitriol and calcitonin. N Engl J Med 1993, 328:1747-52.
114. Homik J, Suárez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P: Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane Review). En: The Cochrane Library, Issue 1, 2001. Oxford: Update Software.
115. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F: A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996, 10:777-86.
116. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, Suarez-Almazor M: Biphosphonates for steroid induced osteoporosis (Cochrane Review). En: The Cochrane Library, Issue 1 2001. Oxford: Update Software.